Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
11.99
-0.81 (-6.33%)
At close: Sep 4, 2026, 4:00 PM EDT
12.07
+0.08 (0.65%)
After-hours: Sep 4, 2026, 7:54 PM EDT
Q32 Bio Revenue
In the year 2025, Q32 Bio had annual revenue of $53.74M.
Revenue (ttm)
$53.74M
Revenue Growth
n/a
P/S Ratio
6.64
Revenue / Employee
$2,442,591
Employees
22
Market Cap
356.94M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.74M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Agenus | 132.69M |
| Century Therapeutics | 109.16M |
| Sutro Biopharma | 45.70M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| Upstream Bio | 3.16M |
| Palisade Bio | 500.00K |
QTTB News
- 6 days ago - Q32 Bio to Participate in Upcoming September Investor Conferences - PRNewsWire
- 14 days ago - Q32 Bio initiated with an Overweight at Morgan Stanley - TheFly
- 4 weeks ago - Q32 Bio Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Q32 Bio Earnings release: Q2 2026 - Filings
- 4 weeks ago - Q32 Bio Slides: Corporate presentation - Filings
- 4 weeks ago - Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - Q32 Bio price target raised to $36 from $13 at H.C. Wainwright - TheFly
- 7 weeks ago - Q32 Bio files to sell 6.88M shares of common stock for holders - TheFly